Premium
Voiding dysfunction in patients with Parkinson's disease: Impact of neurological impairment and clinical parameters
Author(s) -
Sammour Zein M.,
Gomes Cristiano M.,
Barbosa Egberto R.,
Lopes Roberto I.,
Sallem Flávio S.,
TrigoRocha Flavio E.,
Bruschini Homero,
Srougi Miguel
Publication year - 2009
Publication title -
neurourology and urodynamics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 90
eISSN - 1520-6777
pISSN - 0733-2467
DOI - 10.1002/nau.20681
Subject(s) - medicine , nocturia , lower urinary tract symptoms , asymptomatic , parkinson's disease , disease , quality of life (healthcare) , levodopa , severity of illness , urinary system , pediatrics , physical therapy , prostate , nursing , cancer
Aims We assessed the lower urinary tract symptoms (LUTS) of patients with Parkinson's disease (PD) and their association with different clinical parameters. Methods We prospectively evaluated 110 patients (84 men), with a mean age of 61.8 ± 9.6 years. Mean duration of the disease was 12.3 ± 7.2 years. Neurological impairment was assessed by the Hoehn–Yahr and the Unified Parkinson Disease Rating scales. LUTS were assessed by the International Continence Society questionnaire. We evaluated the impact of age, PD duration, neurological impairment, gender, and use of anti‐Parkinsonian drugs on the voiding function. Results On multivariate analysis, voiding dysfunction increased with the neurological impairment, but not with patient's age or disease duration. Quality of life (QOL) was affected by the severity of LUTS, and the symptoms with the worst impact were frequency and nocturia. Sixty‐three (57.2%) patients were symptomatic. They did not differ with the asymptomatic as to age and disease duration, but had more severe neurological impairment. No impact on LUTS was associated with the use of levodopa, anticholinergics, and dopamine receptor agonists. Men and women were similarly affected by urinary symptoms. Conclusions The severity of the neurological disease is the only predictive factor for the occurrence of voiding dysfunction, which affects men and women alike. Neurourol. Urodyn. 28:510–515, 2009. © 2009 Wiley‐Liss, Inc.